Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | New Market Report Now Available: Japan Pharmaceuticals & Healthcare Report Q2 2011New Healthcare market report from Business Monitor International: "Japan Pharmaceuticals & Healthcare Report Q2 2011"
In the meantime, there are three factors that stand in the way of Japan achieving anything other than meagre real GDP growth over the coming decade: demographics; Still, valued at over US$107bn in 2010, Japanese market is the second largest in the world, behind the US and ahead of Germany. Pharmaceutical expenditure as a percentage of GDP is 1.78%, which falls above both regional and global averages. Through to 2015, however, we expect that market growth will be in low single-digit figures, with a five-year local currency compound annual growth rate (CAGR) coming in at 0.69%. Due to unfavourable exchange rates, at this point, the Japanese market will be worth US$96.4bn, although a massive US$78bn of this will still be represented by patented medicines. Generics are expected to increase their penetration of the total market by value, from 8.3% in 2010 to 12.8% in 2015, when they will be worth US$12.3bn, at a local currency CAGR of 9.66%. Clearly, although the potential rewards are substantial, risks do exist, which has promoted local players to increasingly aim to generate their revenues abroad. For example, in October 2010 and several years after other non-Japanese multinationals, Takeda announced its medium- to long-term strategy for India. The company plans to form alliances with local companies to sell its patented drugs. Takeda also intends to offshore many basic business functions - such as medicinal chemistry research. Some players are also looking to enter the Japanese biosmilars market, with Hungarian-based Gedeon Richter and the Japanese drugmaker Mochida recently striking a long-term licensing and collaboration agreement for the development and marketing of the former's biosimilar product portfolio. Japan already has a clear regulatory pathway for biosimilars, which provides a significant advantage to drugmakers. For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: SWOT Analysis - Japan Pharmaceuticals And Healthcare Industry SWOT - Japan Political SWOT - Japan Economic SWOT Pharmaceutical Business Environment Ratings - Table: Asia Pacific - Regional Pharmaceutical Business Environment Ratings, Q211 - Rewards - Risks Japan - Market Summary - Regulatory Regime - Recent Regulatory Developments - Intellectual Property Developments - Pricing and Reimbursement System - Table: Reimbursement Categories And Rates - Recent Pricing and Reimbursement Developments - Other Regulatory Issues - Table: Concerns Of Pharmaceutical Associations Industry Trends and Developments - Epidemiology - Non-Communicable Diseases - Communicable Diseases - Mental Health - Healthcare Sector - Healthcare Sector Financing - Healthcare Reforms - International Reaction - Medical Tourism - Research and Development - Clinical Trials - Medical Devices - Recent Developments in the Medical Devices Market Industry Forecast Scenario - Overall Market Forecast - Table: Pharmaceutical Sales Indicators 2007-2015 - Key Growth Factors - Industry - Table: Healthcare Expenditure Indicators 2007-2015 - Table: Government Healthcare Expenditure Indicators 2007-2015 - Table: Private Healthcare Expenditure Indicators 2007-2015 - Macroeconomic Outlook - Table: Japan - Economic Activity - Prescription Drug Market Forecast - Table: Prescription Drug Sales Indicators 2007-2015 - Patented Drug Market Forecast - Table: Patented Drug Market Indicators 2007-2015 - Generic Drug Market Forecast - Table: Generic Drug Sales Indicators 2007-2015 - OTC Medicine Market Forecast - Table: OTC Medicine Sales Indicators 2007-2015 - Medical Device Market Forecast - Table: Medical Devices Sales Indicators 2007-2015 - Pharmaceutical Trade Forecast - Table: Exports and Imports Indicators 2007-2015 - Other Healthcare Data - Key Risks to BMI's Forecast Scenario Competitive Landscape - Pharmaceutical Industry - Table: Top 20 Pharmaceutical Companies According To Market Capitalisation On The Tokyo Stock Exchange - Foreign Generic Drug Sector - Recent Pharmaceutical Company Developments - Pharmaceutical Wholesale and Retail Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number